Relapsing-remitting multiple sclerosis and Bone loss

Summary:

Bone loss is found among people with Relapsing-remitting multiple sclerosis, especially for people who are female, 30-39 old.

The study analyzes which people have Bone loss with Relapsing-remitting multiple sclerosis. It is created by eHealthMe based on reports of 20 people who have Relapsing-remitting multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 127 drugs and 177 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.

What is Bone loss?

Bone loss is found to be associated with 698 drugs and 557 conditions by eHealthMe. Check the latest studies of Bone loss.

On Jul, 07, 2026

20 people who have Relapsing-Remitting Multiple Sclerosis and Bone Loss are studied.

Would you have Bone loss when you have Relapsing-remitting multiple sclerosis?

Gender of people who have Relapsing-Remitting Multiple Sclerosis and experienced Bone Loss *:

female: 85 %
male: 15 %

Age of people who have Relapsing-Remitting Multiple Sclerosis and experienced Bone Loss *:

Common co-existing conditions for these people *:

Headache (pain in head): 2 people, 10.00%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 5.00%
Pain: 1 person, 5.00%
Migraine (headache): 1 person, 5.00%
Joint Pain: 1 person, 5.00%
Inflammation: 1 person, 5.00%
High Blood Pressure: 1 person, 5.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.00%
Fatigue (feeling of tiredness): 1 person, 5.00%

Common drugs taken by these people *:

Ocrevus: 10 people, 50.00%
Benadryl: 9 people, 45.00%
Methylprednisolone: 7 people, 35.00%
Rebif: 6 people, 30.00%
Solu-Medrol: 5 people, 25.00%
Aubagio: 3 people, 15.00%
Methylprednisolone Sodium Succinate: 3 people, 15.00%
Copaxone: 2 people, 10.00%
Gabapentin: 1 person, 5.00%
Gemzar: 1 person, 5.00%

Common symptoms for these people *:

Fatigue (feeling of tiredness): 12 people, 60.00%
Gingivitis (inflammation of gums): 11 people, 55.00%
Malaise (a feeling of general discomfort or uneasiness): 10 people, 50.00%
Urinary Tract Infection: 10 people, 50.00%
Injection Site Pain: 10 people, 50.00%
Pain: 9 people, 45.00%
Toothaches (tooth pain): 9 people, 45.00%
Dental Caries: 9 people, 45.00%
Stress And Anxiety: 8 people, 40.00%
Memory Loss: 8 people, 40.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Bone loss?

- Check whether Bone loss is associated with a drug or a condition

Related studies:

Treatments, associated drugs and conditions:

Relapsing-remitting multiple sclerosis (76,275 reports)
Bone loss (27,142 reports)

All the drugs that are associated with Bone loss:

Bone loss (698 drugs)

All the conditions that are associated with Bone loss:

Bone loss (557 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Bone loss and Relapsing-remitting multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.